Belimumab for treating lupus nephritis (terminated appraisal) (TA806)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) (TA793)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating lupus nephritis ID6420Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC